Clinical Trials Sponsored by KAI Pharmaceuticals

Total 20382 results

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets

Metastatic Castration-resistant Prostate Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Study of TQB2450 Injection in Subjects With PD-L1 Positive Recurrent or Metastatic Cervical Cancer

Recurrent or Metastatic Cervical Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma （DLBCL）

Diffuse Large B-cell Lymphoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer

Advanced Endometrial Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3454 Tablets

Advanced Solid Tumor or Hematologic Tumor

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma

Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)

Advanced Hepatocellular Carcinoma (HCC)

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)

Stage III Non-small-cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of TQ-B3525 on Tolerance and Pharmacokinetics

Relapsed or Refractory Lymphoma or Advanced Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active, not recruiting

TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients

Myelofibrosis

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Clinical Trial of Safety and Tolerance of TQH3821 Tablets in Adult Healthy Subjects

Rheumatoid Arthritis

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active, not recruiting

To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer

HR-positive, HER2-negative Breast Neoplasms

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Withdrawn

A Clinical Trial of TQB3015 Tablets in Patients With Advanced Malignant Cancer

Advanced Malignant Neoplasm

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active, not recruiting

A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active, not recruiting

Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.

HER2-positive Breast Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

To Evaluate the Effect of Food on the Pharmacokinetics of TQ05105 Tablets in Healthy Adult Subjects

Myelofibrosis

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active, not recruiting

Clinical Trial of the TQB3602 Capsule Combined With AK105 Injection in Patients With Advanced Cancers

Advanced Cancers

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active, not recruiting

A Clinical Study of TQB3823 in Patients With Advanced Malignant Tumor

Advanced Solid Tumor

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active, not recruiting

A Study of TQ05105 Tablets in Subjects With Glucocorticoid-Refractory Acute Graft-Versus-Host Disease (aGVHD)

Glucocorticoid-Refractory aGVHD

China
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.

Enrolling by invitation

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of FHND5071 as a Single Agent in Adult Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Fresenius Kabi Sino-Swed Pharmaceutical Corp. Ltd

Enrolling by invitation

To Test the Food for Special Medical Purpose in Perioperative Patients With Gastrointestinal Cancer

Gastrointestinal Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Bioequivalence Study of Dasatinib Tablet

Leukemia, Myelogenous, Chronic

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Pharmacokinetic Study of TQB3101 in Chinese Healthy Subjects

Pharmacokinetic Study

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Human Bioequivalence Test of Liraglutide Injection

Type 2 Diabetes

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer

Advanced Biliary Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of Recombinant Human Coagulation Factor VIIa for Injection (FⅦa) in Patients With Hemophilia.

Hemophilia A With Inhibitor | Hemophilia B With Inhibitor

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study to Evaluate the Tolerance and Pharmacokinetics of TQB2618 Injection in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Bendamustine Hydrochloride Injection

Indolent B-Cell Non-Hodgkin's Lymphomas

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQ05105 Tablets in Subjects With Hemophagocytic Lymphohistiocytosis（HLH）

Hemophagocytic Lymphohistiocytosis

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor

Advanced Malignant Tumor

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes

Type 2 Diabetes

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets

Non-small Cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.

HER2-positive Metastatic Breast Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQ-B3101 in Subjects With Relapsed or Refractory Anaplastic Large Cell Lymphoma (ALCL)

Relapsed/Refractory Anaplastic Large Cell Lymphoma (ALCL)

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)

Extensive Small Cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3804 in Subjects With Advanced Malignant Tumors

Advanced Malignant Tumors

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)

ALK-positive NSCLC

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of TQB2450 Combined With Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（NSCLC）

Non-small Cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3474 Injection

Advanced Solid Tumor

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy in Subjects With Squamous Non-small Cell Lung Cancer

Squamous Non-small Cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Phase II Study of Anlotinib in STS Patients (ALTN/STS)

Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Phase I Study of TQ-B3234 on Tolerance and Pharmacokinetics

Advanced Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)

Differentiated Thyroid Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Terminated

A Multicenter Randomized Double-blind Clinical Study Evaluated the Safety, Pharmacokinetic and Pharmacodynamic Characteristics of Roflumilast in COPD Patients

Chronic Obstructive Pulmonary Disease

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)

Small Cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients

Advanced Solid Tumors

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Efficacy and Safety of Domestic Tenofovir Tablets in Chinese Patients With Chronic Hepatitis B

Chronic Hepatitis B

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Bioequivalence Study of Entecavir Tablets and Baraclude® Under Fasting Condition in Chinese Healthy Volunteers

Chronic Hepatitis b

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Efficacy and Safety of Entecavir Maleate Tablets in Chinese Patients With Hepatitis B

Chronic Hepatitis B

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0303） (ALTER0303)

Non-small Cell Lung Cancer

China

3

Subscribe